Produkte von TargetMol
TargetMol aus Boston (Massachusetts) wurde 2015 gegründet und ist ein Experte für Wirkstoffscreening in der Life Science-Community. Das Unternehmen bietet diverse Substanzbibliotheken, darunter FDA-zugelassene Bibliotheken, an und deckt ein breites Spektrum an niedermolekularen Verbindungen wie Inhibitoren und Agonisten sowie rekombinante Proteine und Naturstoffe ab. Die Produkte von TargetMol werden von Forschenden weltweit in Bereichen wie Krebsforschung, Neurobiologie, Inflammation, Immunologie oder Metabolismus eingesetzt.
Mehr Informationen unter: www.targetmol.com
Für die Filterung wurden keine Ergebnisse gefunden!
5-(and-6)-Carboxy SNARF-1
Artikelnummer: TGM-TD0096-5mg
Description: 5-(6)-Carboxy RhodFluor is a cell-impermeant pH indicator. References: Charlotte T , Stefan O , Tommy H N , et al. Vital fluorescent stains for detection of stress in Pythium ultimum and Rhizoctonia solani challenged with viscosimide from Pseudomos fluorescens DR54[J]. FEMS Microbiology Ecology(1):1.
| CAS | 126208-12-6 |
| MW: | 453.45 D |
1.543,00 €
CHAPSO
Artikelnummer: TGM-TF0055-500mg
Description: CHAPSO is a nondenaturing, amphoteric descaler, a surface ionic active agent that can be used to solubilize membrane proteins and cleaved protein-protein interactions. Target: Others. Smiles:...
| MW: | 630.88 D |
57,00 €
Pertuzumab
Artikelnummer: TGM-T9909-10mg
Description: Pertuzumab (anti-HER2) a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors impairs the ability of HER2 to bind to other members of the HER family. Target: EGFR. References: Sakai K, et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits...
| MW: | 148 kD |
ab 178,00 €
Eculizumab
Artikelnummer: TGM-T9915-10mg
Description: Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5. Target: Complement System. References: Sheridan D, et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS One. 2018 Apr 12,13(4):e0195909.
| MW: | 148 kD |
ab 169,00 €
Alirocumab
Artikelnummer: TGM-T9916-100mg
Description: Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by recombinant DNA technology in Chinese hamster ovary cell suspension culture. Target: Others. References: Ramanathan A, et al. Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C...
| MW: | 146 kD |
ab 351,00 €
Denosumab
Artikelnummer: TGM-T9917-10mg
Description: Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand. Target: RANKL/RANK. References: Kuritani M, et al. Anti-mouse RANKL Antibodies Inhibit Alveolar Bone Destruction in Periodontitis Model Mice. Biol Pharm Bull.2018,41(4):637-643.
| MW: | 147 kD |
ab 168,00 €
Alemtuzumab
Artikelnummer: TGM-T9919-10mg
Description: Alemtuzumab is a humanized monoclonal antibody against CD52 an antigen found on the surface of normal and malignant lymphocytes. Target: Others, Apoptosis. References: Ruck T, et al. Alemtuzumab in Multiple Sclerosis: Mechanism of Action and Beyond. Int J Mol Sci. 2015 Jul 20,16(7):16414-39.
| MW: | 146.04 kD |
ab 280,00 €
Matuzumab
Artikelnummer: TGM-T9922-10mg
Description: Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR with potential anticancer activity that blocks EGFR activation and downstream signaling for the study of non-small cell lung cancer. Target: EGFR. References: Rob C. Roovers, et al. A bi-paratopic anti-EGFR nanobody efficiently...
| Schlagworte: | EMD72000, EMD-72000, EMD 72000 |
ab 215,00 €
Ofatumumab
Artikelnummer: TGM-T9925-100mg
Description: Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation. Target: Others. References: Barth MJ, et al.Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.Clin Cancer...
| MW: | 149 kD |
ab 225,00 €
Panitumumab
Artikelnummer: TGM-T9927-100mg
Description: Panitumumab is a fully human IgG2 monoclonal antibody targeting the epidermal growth factor receptor EGFR). Target: EGFR. References: Cohenuram M, et al.Panitumumab the first fully human monoclonal antibody: from the bench to the clinic. Anticancer Drugs. 2007 Jan,18(1):7-15.
| Schlagworte: | Panitumumab(anti-EGFR) |
| MW: | 147 kD |
ab 168,00 €
Secukinumab
Artikelnummer: TGM-T9930-10mg
Description: Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis. Target: IL Receptor. References: Frieder J, et al.Secukinumab: a review of the anti-IL-17A biologic...
ab 138,00 €
meplazumab
Artikelnummer: TGM-T9931-10mg
Description: meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. Target: Others. References: Huijie Bian, Zhao-Hui Zheng, Ding Wei,et al.Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial.bioRxiv.2020.
| CAS | 2413715-21-4 |
ab 183,00 €